AbbVie Inc. Goodwill, Other Increase (Decrease)
AbbVie Inc. (ABBV) reported Goodwill, Other Increase (Decrease) of -$121.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes › Goodwill and Other
us-gaap:GoodwillOtherIncreaseDecrease · last filed 2026-08-03
- AbbVie Inc. goodwill, other increase (decrease) for the quarter ending 2026-06-30 was -$51.00M, a 114.45% decline year-over-year.
- AbbVie Inc. goodwill, other increase (decrease) for the quarter ending 2026-03-31 was -$70.00M, a 144.03% decline year-over-year.
- AbbVie Inc. goodwill, other increase (decrease) for the quarter ending 2025-09-30 was -$12.00M, a 105.80% decline year-over-year.
- AbbVie Inc. goodwill, other increase (decrease) for the quarter ending 2025-06-30 was $353.00M.
| Period end | Goodwill, Other Increase (Decrease) 3 month | Goodwill, Other Increase (Decrease) 6 month | Goodwill, Other Increase (Decrease) 9 month |
|---|---|---|---|
| 2026-06-30 | -$51.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$121.00M 10-Q · filed 2026-08-03 | |
| 2026-03-31 | -$70.00M 10-Q · filed 2026-05-08 | ||
| 2025-09-30 | -$12.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $341.00M derived: sum of 2 quarters · filed 2025-11-04 | $500.00M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $353.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $512.00M 10-Q · filed 2025-08-04 | |
| 2025-03-31 | $159.00M 10-Q · filed 2025-05-09 | ||
| 2024-09-30 | $207.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $167.00M derived: sum of 2 quarters · filed 2024-11-04 | $51.00M 10-Q · filed 2024-11-04 |
| 2024-06-30 | -$40.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$156.00M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | -$116.00M 10-Q · filed 2024-05-03 | ||
| 2023-09-30 | -$133.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$129.00M derived: sum of 2 quarters · filed 2023-11-06 | -$65.00M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $4.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $68.00M 10-Q · filed 2023-08-07 | |
| 2023-03-31 | $64.00M 10-Q · filed 2023-05-05 | ||
| 2022-09-30 | -$302.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | -$572.00M derived: sum of 2 quarters · filed 2022-11-04 | -$653.00M 10-Q · filed 2022-11-04 |
| 2022-06-30 | -$270.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$351.00M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | -$81.00M 10-Q · filed 2022-05-06 | ||
| 2021-09-30 | -$102.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | -$264.00M 10-Q · filed 2021-11-02 | |
| 2021-06-30 | -$162.00M 10-Q · filed 2021-08-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |